Anti-Wilms Tumor Protein antibody [CAN-R9(IHC)-56-2]

• Supplier: Abcam
• Catalog: ab89901
• Prices: $400.00
• Sizes: 100 µl
• Host: Rabbit
• Clonality: Monoclonal
• Isotype: IgG
• Clone: CAN-R9(IHC)-56-2
• Applications: IHC-F FC WB IHC-P ICC/IF ICC/IF
• Species Reactivities: Mouse, Human
• Antigen: Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) (GST-tag) corresponding to Human Wilms Tumor Protein aa 50-250
• Description: Rabbit Monoclonal
• Gene: WT1
• Conjugate: Unconjugated

Product images

Anti-Wilms Tumor Protein antibody [CAN-R9(IHC)-56-2] (ab89901) at 1/100 dilution (unpurified) + K562 cell lysate at 10 µgSecondaryPeroxidase-conjugated goat anti-rabbit IgG (H+L) at 1/1000 dilution

Anti-Wilms Tumor Protein antibody [CAN-R9(IHC)-56-2] (ab89901) at 1/1000 dilution (purified) + K562 cell lysate at 10 µgSecondaryPeroxidase-conjugated goat anto-rabbit IgG (H+L) at 1/1000 dilution

Anti-Wilms Tumor Protein antibody [CAN-R9(IHC)-56-2] (ab89901) at 1/1000 dilution (unpurified) + Ramos cell lysate

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human kidney tissue labelling Wilms Tumor Protein with unpurified ab89901 at 1/30. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9. A prediluted HRP-polymer conjugated anti-rabbit IgG was used as the secondary antibody. Counterstained with Hematoxylin.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human kidney tissue labelling Wilms Tumor Protein with purified ab89901 at 1/300. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9. A prediluted HRP-polymer conjugated anti-rabbit IgG was used as the secondary antibody. Counterstained with Hematoxylin.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human Wilms tumor tissue labelling Wilms Tumor Protein with unpurified ab89901 at 1/250.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human fetal tissue labelling Wilms Tumor Protein with unpurified ab89901 at 1/250.

Immunocytochemsitry/Immunofluorescence analysis of K562 cells labelling Wilms Tumor Protein (green) with unpurified ab89901 at 1/50. Cells were fixed with 4% paraformaldehyde. An Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/200) was used as the secondary antibody. Counterstained with DAPI (blue).

Immunocytochemsitry/Immunofluorescence analysis of K562 cells labelling Wilms Tumor Protein (green) with purified ab89901 at 1/50. Cells were fixed with 4% paraformaldehyde. An Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/200) was used as the secondary antibody. Counterstained with DAPI (blue).

Overlay histogram showing K562 cells stained with unpurified ab89901 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab89901, 1/100 dilution) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-rabbit IgG (H+L) (ab96899) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was rabbit IgG (monoclonal) (1µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed.

Flow cytometry analysis of K562 cells labelling Wilms Tumor Protein with unpurified ab89901 at 1/3 (red). Cells were fixed with 2% paraformaldehyde. A FITC-conjugated goat anti-rabbit IgG (1/150) was used as the secondary antibody. Green - Isotype control, rabbit monoclonal IgG.

Flow cytometry analysis of K562 cells labelling Wilms Tumor Protein with purified ab89901 at 1/50 (red). Cells were fixed with 2% paraformaldehyde. A FITC-conjugated goat anti-rabbit IgG (1/150) was used as the secondary antibody. Green - Isotype control, rabbit monoclonal IgG.

Product References

Generation of the epicardial lineage from human pluripotent stem cells. - Generation of the epicardial lineage from human pluripotent stem cells.

Witty AD, Mihic A, Tam RY, Fisher SA, Mikryukov A, Shoichet MS, Li RK, Kattman SJ, Keller G. Nat Biotechnol. 2014 Oct;32(10):1026-35.

Reversibility of structural and functional damage in a model of advanced diabetic - Reversibility of structural and functional damage in a model of advanced diabetic

Pichaiwong W, Hudkins KL, Wietecha T, Nguyen TQ, Tachaudomdach C, Li W, Askari B, Kobayashi T, O'Brien KD, Pippin JW, Shankland SJ, Alpers CE. J Am Soc Nephrol. 2013 Jun;24(7):1088-102.

The modified selenenyl amide, M-hydroxy ebselen, attenuates diabetic nephropathy - The modified selenenyl amide, M-hydroxy ebselen, attenuates diabetic nephropathy

Tan SM, Sharma A, Yuen DY, Stefanovic N, Krippner G, Mugesh G, Chai Z, de Haan JB. PLoS One. 2013 Jul 16;8(7):e69193.

The receptor of advanced glycation end products plays a central role in advanced - The receptor of advanced glycation end products plays a central role in advanced

Zhou LL, Cao W, Xie C, Tian J, Zhou Z, Zhou Q, Zhu P, Li A, Liu Y, Miyata T, Hou FF, Nie J. Kidney Int. 2012 Oct;82(7):759-70.

Reversible cell-cycle entry in adult kidney podocytes through regulated control - Reversible cell-cycle entry in adult kidney podocytes through regulated control

Shkreli M, Sarin KY, Pech MF, Papeta N, Chang W, Brockman SA, Cheung P, Lee E, Kuhnert F, Olson JL, Kuo CJ, Gharavi AG, D'Agati VD, Artandi SE. Nat Med. 2011 Dec 4;18(1):111-9.

Control of epigenetic states by WT1 via regulation of de novo DNA - Control of epigenetic states by WT1 via regulation of de novo DNA

Szemes M, Dallosso AR, Melegh Z, Curry T, Li Y, Rivers C, Uney J, Magdefrau AS, Schwiderski K, Park JH, Brown KW, Shandilya J, Roberts SG, Malik K. Hum Mol Genet. 2013 Jan 1;22(1):74-83.